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Decreasing the intraocular pressure (IOP) is the main 
goal of glaucoma treatment. The Early Manifest Glaucoma 
Trial showed that glaucoma progression decreased by 10% 
with the reduction of each mmHg of IOP [1]. According 
to the Collaborative Normal Tension Glaucoma Study 
Group, an IOP reduction of 30% slowed the progression of 
normal-tension glaucoma (NTG) [2].
Evaluation of the IOP reduction after glaucoma treat-
ment is important for clinical decision-making. A mon-
ocular drug trial is one of the clinical methods used to 
evaluate the amount of IOP reduction after treatment and 
to predict the drug response in the contralateral eye. In a 
monocular drug trial, instillation of a drug is carried out 
for only one eye initially. After a period of time to allow 
the drug to exert sufficient effect, the amount of IOP re-
duction in the treated eye is compared to the changes in 
IOP of the contralateral eye; the untreated eye serves as a 
control to assess the efficacy of the drug. By comparing 
the IOP changes of the two eyes, one can determine the net 
effect of treatment based on diurnal variation and visit-to-
visit variation of the IOP. After evaluating the effects, the 
drug can then be instilled in the contralateral eye or can be 
changed.
Various studies have been performed to evaluate the 
efficacy of monocular drug trials [3-9]. However, studies 
have shown mixed results. Retrospective study design, use 
of beta-blockers, and/or not measuring diurnal variations 
in IOP may cause inconsistent study findings. In addition, 
there is a paucity of prospective clinical trials that have 
evaluated the usefulness of monocular drug trials in eyes 
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Purpose: To evaluate the efficacy of a monocular drug trial in eyes with normal-tension glaucoma (NTG).
Methods: This prospective study enrolled 74 patients with NTG. The monocular drug trial was started using 
latanoprost 0.005% for one week. If the intraocular pressure (IOP) reduction was greater than 15%, the same 
medication was administered to both eyes for one month. The unadjusted change and adjusted change (the 
change in the treated eye minus the change in the contralateral eye) in IOP were evaluated, and the predictors 
of IOP response were analyzed by multivariate linear regression.
Results: Among the initial 74 patients, 31 (41.9%) were included; others were excluded because they did not 
meet the requisite conditions. The most significant predictors of IOP response in the initial eye and subse-
quent eye were the baseline IOPs in both eyes (β = 0.907, 0.771, respectively). The adjusted change in IOP of 
the initial eye had greater association (β = 0.589) with the IOP after monocular trial in the initial eye than that of 
unadjusted IOP change (β = 0.279). The adjusted change in IOP also had greater predictability (β = 0.348) for 
IOP after monocular trial in the subsequent eye than that of the unadjusted IOP change (β = 0.090). 
Conclusions: Although the monocular trial in NTG patients had limited efficacy due to its stringent conditions, it 
was useful for evaluating the IOP response in the initial eye and for predicting the IOP response in the subse-
quent eye.
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with NTG, which is the most common type of glaucoma 
in some Asian countries [10,11]. Therefore, this study was 
performed prospectively to evaluate the efficacy of a mon-
ocular drug trial using latanoprost 0.005% with measure-
ment of the diurnal variation of IOP in eyes with NTG. 
Materials and Methods
This study was approved by the Institutional Review 
Board and adhered to the tenets of the Declaration of Hel-
sinki. All participants provided written informed consent. 
Among the individuals that visited our clinic between Feb-
ruary 2008 and March 2010, those diagnosed with NTG 
with no history of glaucoma treatment were enrolled.
Ocular examinations including visual acuity, slit lamp 
examination, IOP measurements with a Goldmann ap-
planation tonometer, refractive error measurements with 
an autorefractokeratometer (RK-F1; Canon, Tokyo, Japan), 
corneal thickness measurements obtained by specular 
microscope (Topcon SP-2000P; Topcon America Corp, 
Paramus, NJ, USA), gonioscopic examination, retinal 
nerve fiber layer and stereo disc photos, and visual field 
examination (Humphrey Automated Perimetry 30-2 SITA 
program) were performed on all eyes. Glaucomatous disc 
change (i.e., diffuse or localized rim thinning, rim notches, 
increased cupping, or disc hemorrhage) was evaluated 
based on stereo disc photographs (Zeiss FF450 fundus 
camera; Carl Zeiss Meditec, Dublin, CA, USA), and retinal 
nerve fiber layer defect (i.e., increased clarity of vascular 
light reflexes in diffuse atrophy, dark slits or wedges along 
the arcuate bundle) was assessed by red-free fundus pho-
tography (Zeiss FF450 fundus camera; Carl Zeiss Meditec) 
performed by a single examiner. NTG was identified by 
glaucomatous optic disc changes and corresponding retinal 
nerve fiber layer defects with (perimetric glaucoma) or 
without (preperimetric glaucoma) corresponding visual 
field changes, coincident with an IOP <21 mmHg at any 
point during the IOP measurements. Eyes with ocular dis-
eases other than NTG or with refractive errors outside the 
range of ±6 diopters were excluded. The baseline IOP was 
measured at 10:00, 12:00, 14:00, and 16:00 on the same day 
by one examiner (YHH) to confirm the range of IOP <21 
mmHg during at any time of the day. Among the four IOP 
measurements, one IOP was selected as a baseline measure 
according to patient convenience (i.e., if the patient wanted 
to make follow-up visits at 10:00, the IOP of the 10:00 
before treatment was considered as a baseline IOP). Only 
patients with similar IOPs (≤2 mmHg IOP differences) in 
both eyes were included. After evaluating the baseline IOP, 
the patients were instructed to use latanoprost 0.005% in 
only one eye. The initial eye was the eye with the higher 
IOP or more severe visual field defects in those cases with 
similar IOP levels in both eyes.
After the treatment of one eye for one week (monocular 
phase), the IOP changes in both eyes were evaluated using 
unadjusted (absolute) IOP change and adjusted (relative) 
IOP change [6]. The unadjusted IOP change was defined as 
the difference between the baseline IOP and the IOP after 
treatment. The adjusted IOP change was defined as the 
difference between the unadjusted IOP change and IOP 
change of the contralateral eye during the treatment pe-
riod. If the amount of IOP reduction was greater than 15% 
[12] with the adjusted changes, the same medication was 
started in the contralateral eye. After the treatment of both 
eyes with the same drug for one month (binocular phase), 
the unadjusted and adjusted IOP reductions of the initial 
eye and subsequent eye were calculated. At each visit dur-
ing the treatment phase, participants were instructed to 
visit at the same time of day as for the baseline IOP mea-
surements. Any patients who did not visit at the indicated 
time or day were excluded. All of the IOP measurements 
were performed by the same examiner (YHH) who was 
blinded to whether the individual was enrolled in the mon-
ocular phase or binocular phase and to which eye was ini-
tially treated.
When considering the initial eye as B, the subsequent 
eye as A, the baseline visit as 1, visit after the monocular 
phase as 2, and visit after the binocular phase as 3, unad-
justed and adjusted IOP changes were identified as fol-
lows: unadjusted IOP change in the initial eye (B2 – B1), 
adjusted IOP change in the initial eye (B2 – B1) – (A2 – 
A1), unadjusted IOP change in the subsequent eye (A3 – 
[A1 + A2] / 2), and adjusted IOP change in the subsequent 
eye (A3 – [A1 + A2] / 2) – (B3 – B2). As previous studies 
have recommended measuring multiple baseline IOPs, the 
average of A1 and A2 was considered as the baseline IOP 
of the subsequent eye during the binocular phase [8,9]. 
Distributions of all variables were examined for normality 
using the Kolmogorov Smirnov 1-sample test. The baseline 
IOP, spherical equivalent (spherical refractive error +1/2 
cylindrical refractive error in the negative form), visual 
field indices, and central corneal thickness of the initial 
eye and subsequent eye were compared by paired t-test 
or Wilcoxon signed rank test. Because the purpose of the 
present study was to evaluate the predictive value of base-
line IOP, unadjusted IOP change, and adjusted IOP change, 
multivariate linear regression analysis was performed to 
determine the predictors of IOP response in both eyes. To 
evaluate the predictors of the initial eye, B3 was consid-
ered as the dependent variable, and B1, B2 – B1, and (B2 – 
B1) – (A2 – A1) were considered as independent variables. 
On the other hand, A3 was set as the dependent variable 
for evaluation of predictors of the subsequent eye, and (A1 
+ A2) / 2, B2 – B1, and (B2 – B1) – (A2 – A1) were consid-
ered as independent variables. The clinical value of signifi-
cance was set at p < 0.05 for all analyses.28
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Results
Seventy-four Korean NTG patients with no history of 
glaucoma medication usage were considered during the 
study period. Among them, 31 patients (41.9%) were in-
cluded in the study. 
Others were excluded due to asymmetric diurnal varia-
tion in baseline IOP (5 patients, 6.8%), insufficient re-
sponse to the drug (7 patients, 9.5%), missing more than 
25% of total doses based on the patient’s own admission (8 
patients, 10.8%), administration of eye drops to the wrong 
eye or both eyes in the monocular phase (2 patients, 2.7%), 
cessation of eye drops owing to side effects such as con-
junctival injection and stinging sensation (3 patients, 4.1%), 
not measuring IOP by the same examiner (1 patient, 1.3%), 
and failure to measure the IOP at the indicated time or day 
during the monocular or binocular treatment phases (17 
patients, 23.0%).
The characteristics of the 31 patients are listed in Table 1. 
Among the 31 patients, 19 were male (61.3%) and 12 were 
female (38.7%). The mean age of the patients was 55.13 ± 
12.99 years (range, 22 to 82 years). There were no significant 
differences in spherical equivalent or central corneal thick-
ness between the initial eye and subsequent eye; whereas, 
visual field indices of the initial eye were worse than those 
of the subsequent eye (Table 1). The baseline IOP values 
of both eyes are shown in Table 2. The difference between 
the two eyes was equal to or less than 2 mmHg at each 
of the four measurements. The IOP of the initial eye was 
equal to or greater than that of the contralateral eye (paired 
t-test) (Table 2).
The Kolmogorov-Smirnov test showed that all of the 
IOP variables used in this study fulfilled the requirements 
for parametric statistics (p > 0.05). The effect of multicol-
linearity was not significant (variance influence factors of 
all variables were less than 10). The amount of IOP reduc-
tion at each treatment phase is listed in Table 3, and pre-
dictors of IOP response in the initial eye and subsequent 
eye are listed in Table 4. The most significant predictors 
for IOP response in the initial eye and subsequent eye were 
baseline IOPs in both eyes (β = 0.907, 0.771, respectively); 
eyes with a higher baseline IOP had greater IOP response. 
The adjusted IOP change in the initial eye had greater as-
sociation (β = 0.589) with the IOP after a monocular trial 
in the initial eye than that of unadjusted IOP change (β = 
0.279). The adjusted IOP change of the initial eye also had 
greater predictability (β = 0.348) for IOP after a monocu-
lar trial in the subsequent eye than that of unadjusted IOP 
change (β = 0.090).
Table 1. Patient characteristics
Mean ± SD (n = 31) p-value
Age (yr)   55.13 ± 12.99
Female / male (%)     12 / 19 (38.7 / 61.3)
Refractive error (diopter)      0.427
*
Initial eye    -1.76 ± 1.95
Subsequent eye    -1.67 ± 1.99
Central corneal thickness (µm)     0.156
*
Initial eye    533.29 ± 28.22
Subsequent eye    535.87 ± 26.10
MD (dB)   <0.001
†
Initial eye    -3.95 ± 2.33
Subsequent eye    -3.12 ± 1.73
PSD (dB)   <0.001
†
Initial eye    4.10 ± 2.51
Subsequent eye    3.05 ± 1.44
Table 2. Baseline intraocular pressure of the initial eye and 
the subsequent eye
Time Initial eye (n = 31) Subsequent eye (n = 31) p-value
*
10:00   15.96 ± 2.82   15.32 ± 2.68 0.003
12:00   16.00 ± 2.70   15.69 ± 2.71 0.118
14:00   15.92 ± 2.64   15.27 ± 2.63 0.004
16:00   16.54 ± 2.82   15.71 ± 2.54 0.001
Values are presented as mean ± SD (mmHg).
*Paired t-test.
MD = mean deviation, PSD = pattern standard deviation. 
*Paired t-test between initial eye and subsequent eye; 
†Wilcoxon signed rank test between initial eye and subsequent eye.29
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Discussion
The American Academy of Ophthalmology’s Preferred 
Practice Pattern for Primary Open-Angle Glaucoma rec-
ommends the use of a monocular drug trial when starting 
a new topical glaucoma medication [13]. However, the 
efficacy of a monocular drug trial in the clinical setting 
continues to be debated. Smith and Wandel [14] described 
the ideal situations for a monocular drug trial: “1) Both 
eyes have the same IOP at the beginning of the trial. 2) 
Both eyes have the same diurnal IOP curve; 3) medica-
tion applied to one eye does not influence the IOP of the 
other eye, to a degree sufficient to influence the IOP of the 
other eye, to influence judgment of therapeutic efficacy.” 
Therefore, to evaluate the efficacy of a monocular drug 
trial, pretreatment diurnal IOP measurement is needed to 
achieve patient-specific information about symmetry and 
variability. To minimize the contralateral effect of topical 
medication, beta-blockers, known to have contralateral ef-
fects, should be avoided [15].
In the present prospective study, only eyes with NTG 
and no history of previous glaucoma treatment were in-
cluded. Further, only latanoprost 0.005% was used for the 
treatment, and baseline IOPs at four different time points 
were recorded to identify symmetric diurnal IOP changes. 
Lastly, both unadjusted and adjusted IOP changes were 
estimated at a similar time of day during the monocular 
and binocular treatment phases. According to the present 
study, the adjusted change in the IOP of the initial eye had 
greater association with the IOP after a monocular trial 
in the initial eye, as well as greater predictability for IOP 
after a monocular trial in the subsequent eye, compared to 
that of the unadjusted IOP change. These results highlight 
the efficacy of a monocular drug trial in eyes with NTG. 
This is the first prospective study demonstrating the effi-
cacy of a monocular drug trial in eyes with NTG.
The Ocular Hypertension Treatment Study (OHTS) re-
ported that the variability of IOP measurements within the 
same eye was greater than the variability of IOP measure-
ments between the eyes [16]. That is, the contralateral eye 
can serve as a better control for IOP variability than the 
same eye treated, and therefore adjusted IOP changes can 
diminish the variability of IOP measurements more than 
can unadjusted IOP changes. The results of the OHTS may 
explain why adjusted IOP changes had greater predictabil-
ity than unadjusted IOP changes for the evaluation of IOP 
response in our study.
Previous studies evaluated the efficacy of a monocular 
drug trial with various types of glaucoma and different 
methods. A retrospective study by Dayanir et al. [4] re-
Table 4. Predictors of intraocular pressure response in the initial eye and the subsequent eye
Initial eye (R
2 = 0.637) Subsequent eye (R
2 = 0.514)
Standardized β p-value
*  Standardized β p-value
* 
Baseline IOP (B1 and [A1 + A2] / 2) 0.907 <0.001 0.771 <0.001
Unadjusted IOP change in the initial eye (B2 – B1)  0.279 0.252 0.090 0.730
Adjusted IOP change in the initial eye ([B2 – B1] – [A2 – A1])  0.589 <0.001 0.348 0.015
IOP = intraocular pressure; B = initial eye; A = subsequent eye; 1 = baseline visit; 2 = visit after the monocular phase.
*Multivariate linear regression.
Table 3. The amount of IOP reduction after the monocular trial 
Phase (n = 31) IOP (mmHg)
Baseline IOP of the initial eye (at visit 1): B1    16.23 ± 2.69
Monocular (at visit 2)
Unadjusted IOP change of the initial eye: (B2 – B1)   -3.94 ± 1.95
Adjusted IOP change of the initial eye:  (B2 – B1) – (A2 – A1)   -3.55 ± 1.63
Baseline IOP of the subsequent eye (at visit 1 & 2): (A1 + A2) / 2     15.32 ± 2.60
Binocular (at visit 3)
Unadjusted IOP change of the subsequent eye: A3 – (A1 + A2) / 2    -3.13 ± 2.04
Adjusted IOP change of the subsequent eye: (A3 – [A1 + A2] / 2) – (B3 – B2)    -2.81 ± 1.83
Values are presented as mean ± SD.
IOP = intraocular pressure; B = initial eye; A = subsequent eye; 1 = baseline visit; 2 = visit after the monocular phase; 3 = visit after the 
binocular phase.30
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ported that there was a significant correlation of the IOP 
response in the initial eye (adjusted IOP change) and that 
of the subsequent eye (unadjusted IOP change) in patients 
with high tension glaucoma, whereas this relationship was 
not significant in patients with normal tension glaucoma. 
Another retrospective study documented that a correlation 
between the two eyes was higher when using adjusted IOP 
changes [5]. Chaudhary et al. [6] retrospectively analyzed 
the correlation of unadjusted and adjusted IOP changes 
in eyes with primary open-angle glaucoma and suspected 
glaucoma, and the correlation was stronger when using ad-
justed changes. The results of these studies are in line with 
the present study in terms of adjusting IOP change.
On the other hand, in normal individuals, the contralat-
eral eyes did not respond symmetrically to a monocular 
drug trial according to the unadjusted IOP change or the 
adjusted IOP change [7]. Another study reported that the 
best predictors of post-treatment IOP of the trial eye and 
the contralateral eye were the baseline IOP and unadjusted 
IOP change, not the adjusted IOP change [8]. Their study 
also demonstrated that monocular and binocular trials had 
similar predictive value. Recently, Realini [9] performed a 
prospective, randomized evaluation of the monocular drug 
trial in patients with ocular hypertension or open-angle 
glaucoma. According to the analysis, neither the unad-
justed IOP change in the initial eye nor the adjusted IOP 
change in the initial eye showed a significant correlation 
with long-term (unadjusted) IOP change in the subsequent 
eye. The differences between these studies and the present 
study may be attributed to the differences in methodology 
or diagnosis of the participants.
There are controversies with regard to the statistical 
methodology used in the analysis of monocular trials [17]. 
Based on the definition of adjusted IOP change in previ-
ous studies, analyzing correlations between the adjusted 
IOP of the eye initially treated ([B2 – B1] – [A2 – A1]) and 
the adjusted IOP of the subsequent eye ([A3 – A2] – [B3 
– B2]) could have artificial effects because both values 
include ‘B2 – A2’ or ‘minus A2.’ To exclude this artificial 
effect, we performed multivariate analysis as described in 
Leffler and Amini’s methods [8], and used (A1 + A2) / 2 
as the baseline IOP of the subsequent eye, as suggested by 
previous studies [8,9]. However, measuring the baseline 
IOP of the initial eye one time only and a relatively small 
number of patients remain limitations of the present study.
From a practical point of view, it may be difficult to 
meet the stringent conditions of the monocular drug trial 
applied in our study. In the present study, a large number 
of patients were excluded because they did not meet the 
requisite criteria. We think that to evaluate the efficacy 
of something, its conditions should be stringently upheld. 
To date, no study has met all the criteria of the monocular 
trial, which is why we excluded many patients who did 
not meet our conditions. Our high exclusion rate may be 
a limitation of the monocular trial and an explanation of 
why the monocular trial is not universally being performed 
despite being recommended [13].
In the present study, among the 74 NTG patients, 7 (9.5%) 
exhibited an insufficient response (less than 15% of IOP 
reduction). According to the study results of the Latano-
prost Study Group, the percentage of non-responders to 
latanoprost was 10%. However, it is difficult to compare 
the rate of that study with ours because they evaluated 
only unadjusted IOP, and the baseline IOP (24.4 ± 0.3 
mmHg) observed was higher than in our study [12]. In 
the present study, we excluded eyes with an adjusted IOP 
reduction less than 15% after one week of administering 
the eye drops in one eye. Camras et al. [12] also used this 
cut-off value to evaluate the percentage of non-responders. 
When considering if a portion of non-responders would be 
converted to responders as the treatment period continues, 
as in the Latanoprost Study Group, a study protocol with a 
longer monocular phase would be better. However, we are 
not sure whether it would affect the study results because 
only 7 patients (9.5%) were excluded owing to insufficient 
IOP reduction during the monocular trial, and the IOP 
changes after one week were reported as minimal [18,19].
In conclusion, although the monocular trial in NTG pa-
tients had limited efficacy due to its stringent conditions, 
it seems to be a useful method for evaluating IOP response 
in the initial eye and for predicting IOP response in the 
subsequent eye.
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